HELP:NASDAQ
Cybin Inc
5,61 $
arrow_downward
−2,43%(−0,14) 1 p
5,70 $
arrow_upward
+1,60% (+0,090)todayEnne avanemist
Suletud: 24. apr, 16:00:00 GMT −4 · USD
search
Kõik sümbolid
1 p
5 p
1 kuu
6 kuud
YTD
1 a
5 a
MAX
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse HELP põhistatistika genereerimine…
Ava
5,95 $
Kõrge
6,18 $
Madal
5,51 $
Keskm. maht
1,13 mln
Maht
10,13 tuh
52 näd kõrgeim
8,97 $
52 näd madalaim
4,29 $
Beeta
1,03
Käibivad aktsiad
50,04 mln
Töötajate arv
50
Uudised
Erinevatest veebiallikatest
AOL.com
·
2 minuti eest
Scaramucci's 'Biggest Investing Mistake Has Always Been Selling Too Early'
TheStreet
·
22 minuti eest
Nasdaq’s CEO declared the stock market is about to change forever
The Manila Times
·
25 minuti eest
urban-gro, Inc. (Nasdaq: UGRO) Issues Comprehensive Business Update: Strategic Transformation from Controlled Environment Agriculture to Sports, Media, and Experiential Platform; Restored Nasdaq Listing Compliance; Cricket Strategy Aligned with LA28
GlobeNewswire
·
29 minuti eest
Greenlane Holdings Regains Compliance with Nasdaq Minimum Bid Price Requirement
Profiil
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Teave üksuse Cybin Inc kohta
AI genereeritud sisu võib sisaldada vigu. Lisateave